Results 31 to 40 of about 882 (153)

Figure showing vaborbactam binding in the active site of P. aeruginosa PBP3.

, 2021
A, Close-up view of vaborbactam in the PBP3 active site. Hydrogen bonds are depicted as dashed lines. Atom coloring is as in Fig 4. The two conformations of the aminothiazole containing moiety of vaborbactam are indicated by labels ‘a’ and ‘b’ near their
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Structure and electron density of vaborbactam bound covalently in the active site of P. aeruginosa PBP3.

, 2021
A, simplified diagram of the crystal structure of PBP3 complexed to vaborbactam. The catalytic domain is colored grey; the N-terminal domain is in green. Vaborbactam is depicted in spheres with the carbon atoms in cyan.
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 2

, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958), Amelie Bosphore (14549900), Antoine Roux (14549894), Eric Farfour (11021923), Corentine Alauzet (14549885), Lise Cremet (14549888), Louise Ruffier d’Epenoux (14549879), Sophie Moussalih (14549891), Marc Vasse (335648), Sylvie C de Verdiere (14549897), Stephane Corvec (14549903), Anaelle Muggeo (14549882)   +11 more
core   +1 more source

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli

Biomolecules, 2020
Resistance to β-lactam antibacterials, importantly via production of β-lactamases, threatens their widespread use. Bicyclic boronates show promise as clinically useful, dual-action inhibitors of both serine- (SBL) and metallo- (MBL) β-lactamases.
Pauline A. Lang, Anete Parkova, Thomas M. Leissing, Karina Calvopiña, Ricky Cain, Alen Krajnc, Tharindi D. Panduwawala, Jules Philippe, Colin W. G. Fishwick, Peteris Trapencieris, Malcolm G. P. Page, Christopher J. Schofield, Jürgen Brem   +12 more
doaj   +1 more source

Meropenem/vaborbactam activity in vitro: a new option for Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae treatment

, 2021
Aim: Infections by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae represent a major challenge because of limited treatment strategies. New β-lactam/β-lactamase inhibitor associations may help to deal with this challenge.
Romanelli, Federica, Morea, Anna, Prete, Raffaele Del, Mosca, Adriana, Stolfa, Stefania, Chironna, Maria, Santacroce, Luigi, Ronga, Luigi   +7 more
core   +1 more source

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model

Antimicrobial Agents and Chemotherapy
Meropenem/vaborbactam is a preferred treatment option for KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, but clinical cure rates remain suboptimal when it is used alone.
Nidhi Singh, Christin M. L. Jogan, Yanan Zang, Xindi Shan, Yinzhi Lang, Arunkumar Karunanidhi, Jackson V. Watkins, Brooke N. Curry, Pranita D. Tamma, Sophie H. Nozick, Egon A. Ozer, Alan R. Hauser, Jürgen B. Bulitta, Zackery P. Bulman   +13 more
doaj   +1 more source

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Pharmacy, 2019
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover, Katie E. Barber, Jamie L. Wagner   +2 more
doaj   +1 more source

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex

Microbiology Spectrum, 2023
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives.
Elin Economou Lundeberg, Viktoria Andersson, Maria Wijkander, Ramona Groenheit, Mikael Mansjö, Jim Werngren, Teresa Cortes, Ivan Barilar, Stefan Niemann, Matthias Merker, Claudio U. Köser, Lina Davies Forsman   +11 more
doaj   +1 more source

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics

Frontiers in Microbiology, 2021
QPX7728 is a novel β-lactamase inhibitor (BLI) that belongs to a class of cyclic boronates. The first member of this class, vaborbactam, is a BLI in the recently approved Vabomere (meropenem-vaborbactam).
Olga Lomovskaya, Ruslan Tsivkovski, Dongxu Sun, Raja Reddy, Maxim Totrov, Scott Hecker, David Griffith, Jeffery Loutit, Michael Dudley   +8 more
doaj   +1 more source